Does Ozempic cause diabetes? Breaking down the claim

What did @drbrunoduartee actually say?

Honestly, this is a difficult video to fact-check in the traditional sense. The transcript we have for this video is largely incoherent, likely the result of a failed auto-transcription from Portuguese into English. The caption, however, tells us the core question being addressed: "ozempic causa diabete?" which translates to "does Ozempic cause diabetes?"

Given the creator's handle includes "medico" (doctor in Portuguese) and the hashtag references healthy weight loss, the video appears to be a response to a viewer asking whether semaglutide (Ozempic) causes diabetes. We cannot quote the creator directly from this transcript, so our fact-check focuses on the underlying medical claim that the video's caption poses, which is itself a question worth answering thoroughly.

Does the science back up the premise of this question?

The short answer: No, Ozempic does not cause diabetes. In fact, it does the opposite for most people who use it. The fear likely stems from a misunderstanding of what the drug actually does to blood sugar, and it is a fear worth correcting directly.

Semaglutide is a GLP-1 receptor agonist originally approved by the FDA in 2017 for type 2 diabetes management. The SUSTAIN trial program, including SUSTAIN-6 (Marso et al., 2016, New England Journal of Medicine), showed that semaglutide significantly reduced HbA1c levels and cardiovascular events in patients with type 2 diabetes. It does not trigger insulin secretion when blood glucose is low, which is why hypoglycemia risk is relatively low compared to older diabetes drugs like sulfonylureas. The mechanism is glucose-dependent, meaning the drug only stimulates insulin release when blood sugar is already elevated.

There is no peer-reviewed evidence that semaglutide causes diabetes. The question itself reflects a common misconception circulating on social media.

What did they get wrong, or right?

Because we cannot parse the actual spoken content from this transcript, we cannot confirm or deny what specific points the creator made. However, if the video's purpose was to refute the idea that Ozempic causes diabetes, that is a medically defensible position to take.

What we can flag is the broader ecosystem of misinformation this video is responding to. The confusion often comes from a few sources. First, some patients on Ozempic experience nausea and reduced appetite, which leads them to eat less, and some people conflate changes in glucose metabolism with causing diabetes. Second, there is legitimate discussion in the literature about pancreatitis risk with GLP-1 agonists, though causality remains debated (Tkáč et al., 2019, Diabetes, Obesity and Metabolism). Third, some social media users confuse Ozempic with insulin, which can cause hypoglycemia. These are distinct drug classes with different mechanisms entirely.

If the creator correctly addressed any of these points, they deserve credit for pushing back on misinformation. Without a readable transcript, we simply cannot grade the specific execution.

What should you actually know?

Here is what the clinical evidence clearly supports, regardless of what any TikTok video says. Semaglutide does not cause diabetes. It was developed to treat type 2 diabetes and has been studied in trials involving tens of thousands of patients. The STEP trials (Wilding et al., 2021, New England Journal of Medicine) confirmed its efficacy for weight loss in people without diabetes, with no signal of diabetes induction in the trial data.

That said, stopping semaglutide abruptly after long-term use can lead to weight regain, and weight regain is a known risk factor for developing type 2 diabetes in predisposed individuals. This is probably where some of the confusion originates. The drug itself is not the problem. Discontinuation without a broader metabolic management plan can leave people worse off than before starting, and that is a legitimate clinical conversation to have with a prescribing physician.

• Ozempic (semaglutide) was FDA-approved for type 2 diabetes management in 2017.
• GLP-1 receptor agonists lower blood sugar through a glucose-dependent mechanism, meaning they do not cause hypoglycemia on their own.
• No large-scale trial has demonstrated that semaglutide induces diabetes in patients.
• Weight regain after stopping GLP-1 drugs is well-documented and may carry metabolic risk for some patients.